Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$3.59 – $4.13
Volume7,056
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.29M
Price / earnings
—
Price / book
265.79×
Price / sales
—
EV / sales
—
EV / EBITDA
0.2×
Profitability
Earnings per share
-$10.28
Return on assets
-159.1%
Return on equity
-66,164%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1×
Quick ratio
1×
Cash ratio
0.97×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$32.65M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PASG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.44M
$6.87M
$4.79M
$4.92M
$4.35M
$4.52M
$6.09M
$4.71M
Research and development
$1.5M
$3.34M
$4.09M
$5.42M
$4.31M
$5.81M
$7.74M
$9.56M
Total operating expenses
$4.94M
$8.27M
$8.88M
$13.85M
$8.66M
$10.33M
$16.46M
$14.27M
Operating income
-$4.94M
-$8.27M
-$8.88M
-$13.85M
-$8.66M
-$10.33M
-$16.46M
-$14.27M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.72M
-$7.82M
-$7.56M
-$12.98M
-$7.75M
-$9.39M
-$15.41M
-$12.73M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.72M
-$7.82M
-$7.56M
-$12.98M
-$7.75M
-$9.39M
-$15.41M
-$12.73M
Net income attributable to common shareholders
-$4.72M
-$7.82M
-$7.56M
-$12.98M
-$7.75M
-$9.39M
-$15.41M
-$12.73M
EBITDA
-$4.94M
-$10.19M
-$8.75M
-$10.16M
-$8.47M
-$10.17M
-$13.62M
-$13.55M
Basic earnings per share
-$1.47
-$2.44
-$2.36
-$4.08
-$2.44
-$2.96
-$4.87
-$3.96
Diluted earnings per share
-$1.47
-$2.44
-$2.36
-$4.08
-$2.44
-$2.96
-$4.87
-$3.96
Recent news
Company coverage with links to the original publishers.
Class action law firm Monteverde & Associates PC is investigating four proposed mergers to determine if shareholders are receiving fair deal terms. The investigations cover Bowman Consulting Group's sale to Bernhard Capital Partners ($43.00/share), Utz Brands' sale to Intersnack Group ($14.25/share with vote on Nov 13), Passage Bio's merger with Remix Therapeutics (vote on Nov 5), and Finward Bancorp's sale to First Financial Bancorp (1.35 share exchange ratio with vote on Nov 2).
Class action law firm Monteverde & Associates PC is investigating four major merger and acquisition transactions to determine if shareholders are receiving fair deal terms. The investigations involve Utz Brands' sale to Intersnack Group, Safety Insurance Group's sale to Mapfre affiliate, Passage Bio's merger with Remix Therapeutics, and Finward Bancorp's sale to First Financial Bancorp.
The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.
The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.
Passage Bio, a clinical-stage genetic medicines company, announced that it will participate in upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Global Biopharma Conference.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.